One small-cap growth stock I’d consider ahead of Fevertree Drinks plc

This smaller company could offer better value for money than Fevertree Drinks plc (LON: FEVR).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The performance of Fevertree (LSE: FEVR) in 2017 has been superb. The drinks company has delivered a rise in its share price of 71%, with investor sentiment improving as a result of upgrades to its guidance for the full year. The company is now forecast to record a rise in its bottom line of 60% in the current year, which suggests the business is performing well.

However, after such a large share price rise, the stock appears to be somewhat overvalued. Therefore, this smaller company could be worth a closer look for the long run.

Improving performance

The company in question is building services group T Clarke (LSE: CTO). It released a generally positive trading update on Friday, with its performance in the period since 1 July being upbeat. It is expecting to deliver results which are in line with guidance for the full year, with pre-tax profit due to be £6.5m and revenue expected to be higher than £300m.

The company’s forward order book now stands at £380m versus £320m at the same time last year. The integration of recently acquired ETON Associates seems to be progressing as planned. Alongside investment in its new off-site prefabrication manufacturing facility at Stansted, it could provide a catalyst for future growth. With continued demand for its specialist services and the company winning a number of contracts recently, its operational and financial performance could improve in future.

Valuation

Looking ahead, T Clarke is forecast to post a rise in its bottom line of 5% in the current year, followed by further growth of 8% next year. This puts it on a price-to-earnings growth (PEG) ratio of just 0.7, which suggests that it may offer a wide margin of safety. Since the company has a price-to-earnings (P/E) ratio of around 6, it offers a dividend yield of 4.6% from a shareholder payout that is covered 3.5 times by profit. This indicates that there could be dividend growth ahead.

In contrast, Fevertree seems to have a relatively high valuation. The company’s P/E ratio of 60 may be easy to justify in the current year when earnings are due to rise by 60%. However, the financial performance is set to be less impressive next year. Its bottom line is expected to grow by just 4%, which puts it on a PEG ratio of around 13. This indicates that there may be a lack of upside potential on offer after an extremely profitable 2017 for investors.

In addition, Fevertree yields just 0.5% from a dividend which is covered 3.9 times by profit. While dividend growth may be high, its income return lags inflation.

Takeaway

While Fevertree Drinks has experienced a stunning 2017, next year may not be so prosperous for its investors. A high valuation and lack of strong earnings growth could make other companies such as T Clarke worth a closer look at the present time. Certainly, small-caps can be relatively risky, but the potential rewards may also be high.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »